Ana Segarra-Brechtel, MD
Psychiatry · Suwanee, GANPI 1952596157
Payments from drug & device makers
Across 270 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$413
- Johnson & Johnson$382
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$358
- Sunovion Pharmaceuticals Inc.$307
- Takeda Pharmaceuticals U.S.A., Inc.$270
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,48799%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,062 |
| Alkermes, Inc. | 22 | $413 |
| Johnson & Johnson | 17 | $382 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $358 |
| Sunovion Pharmaceuticals Inc. | 18 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $270 |
| Lundbeck LLC | 11 | $217 |
| Neos Therapeutics, LP | 19 | $208 |
| Supernus Pharmaceuticals, Inc. | 12 | $200 |
| Otsuka America Pharmaceutical, Inc. | 10 | $175 |
| Neurocrine Biosciences, Inc. | 6 | $107 |
| Ironshore Pharmaceuticals Inc. | 7 | $106 |
| Avanir Pharmaceuticals, Inc. | 5 | $105 |
| Tris Pharma Inc | 6 | $102 |
| E.r. Squibb & Sons, L.L.C. | 4 | $89 |
| Corium, LLC | 4 | $78 |
| Adlon Therapeutics L.p. | 4 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Shire North American Group Inc | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$4,519 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paroxetine CrParoxetine Hcl | 25 | $1,195 |
| Bupropion XlBupropion Hcl | 44 | $1,099 |
| Vilazodone Hcl | 22 | $1,030 |
| Ziprasidone Hcl | 17 | $803 |
| Paroxetine ErParoxetine Hcl | 20 | $729 |
| Sertraline Hcl | 46 | $706 |
| Quetiapine Fumarate | 33 | $458 |
| Bupropion Hcl SrBupropion Hcl | 21 | $260 |
| Duloxetine Hcl | 29 | $240 |
| Fluvoxamine Maleate | 11 | $166 |
| Trazodone Hcl | 41 | $152 |
| Propranolol Hcl | 14 | $116 |
| Fluoxetine Hcl | 19 | $116 |
| Olanzapine | 11 | $113 |
| Paroxetine Hcl | 14 | $72 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Suwanee
- Jagan ChilakamarriSuwanee$25K
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.